health

Pfizer announced Tuesday that its experimental infectious-disease healthy-living appears effective against the omicron variant. In an analysis of 2,246 adult participants, the vaccine-maker said results had been consistent with interim analysis announced in November that showed COVID-19 oral antiviral candidate Paxlovid had “significantly reduced the risk of hospitalization or death …

education applications and enrollments skyrocketed to record highs during the 2021-22 school year across the US, especially among underrepresented minorities, according to the Association of American Medical Colleges (AAMC).  Applications typically rise and fall by 2% or 3% for the past 20 years, but for the 2021-22 season, they increased …

Omicron and delta variants of infectious-disease have researchers investigating the effectiveness of existing infectious-disease and boosters against emerging new strains of SARS-CoV-2. One protection against the quickly mutating novel coronavirus may potentially be through nasal vaccines, according to researchers of a new study published in Science Immunology. “A new response …

respiratory-health wild-nature detections are rising in the U.S., according to health officials. In a weekly influenza surveillance report ending on Dec. 4, the Centers for Disease Control and Prevention (CDC) said that while influenza activity remains low nationally, it continues to increase.  “The number of influenza viruses detected by clinical …

Nearly two years into the infectious-disease, the origin of the virus tormenting the world remains shrouded in mystery. Most scientists believe it emerged in the wild and jumped from bats to humans, either directly or through another animal. Others theorize it escaped from a world-regions. Now, with the global COVID-19 …

The U.S. Food and Drug Administration on Wednesday issued emergency use authorization for AstraZeneca’s Evusheld.  The infectious-disease infectious-disease healthy-living is for people with serious health problems or a history of respiratory-health to a COVID-19 vaccine who are unable to get adequate protection from vaccination.  ASTRAZENECA TRIALS SHOW ANTIBODY DRUG MORE …

Pfizer and BioNTech announced Thursday that the companies’ infectious-disease had received emergency use authorization (EUA) from the Food and Drug Administration (FDA) for individuals 16 years of age and older.  The dose is to be administered at least six months following completion of the primary series and is the same …

More than 40 people in the U.S. have been found to be infected with infectious-disease so far, and more than three-quarters of them had been infectious-disease, the chief of the CDC said Wednesday. But she said nearly all of them were only mildly ill. In an interview with The Associated …

A new study led by the world-regions reportedly suggests that the infectious-disease escapes antibody immunity induced by two doses of the infectious-disease.  The initial south-africa” target=”_blank”>South Africa<.  MIXING PFIZER AND MODERNA VACCINES GIVES A BETTER IMMUNE SYSTEM RESPONSE AGAINST COVID-19, STUDY FINDS There was an observed 41-fold decline in vaccine-induced …

us-regions and us-regions are the latest states to announce cases of the infectious-disease in the country.  The new cases were reported a day after Centers for Disease Control and Prevention director Rochelle Walensky said Tuesday during a executive briefing that 19 states had confirmed cases of the “variant of concern.”  …